NIKI

Niki BioSolutions, Inc. NIKI

NasdaqunknownTechnology

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$74.2K total
JANE STREET GROUP, LLC
$45.7KNew
CITADEL ADVISORS LLC
$19.2K-73.5%
CITIGROUP INC
$5.0KNew
OSAIC HOLDINGS, INC.
$4.3K0.0%
SBI Securities Co., Ltd.
$50.0%
See all 5 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NIKI

Loading ratio trend…

NIKI key financials by period

Reported revenue, net income and operating margin by fiscal year, from Niki BioSolutions, Inc.'s annual filings on SEC EDGAR.

Niki BioSolutions, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$431.4K$-2.8M—
FY 2022$1.3M$-9.8M—
FY 2021$1.5M$-25.0M—
Source: NIKI filings on SEC EDGAR →

NIKI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Niki BioSolutions, Inc. (NIKI): stock profile, AI score and financials

Niki BioSolutions, Inc. (NIKI) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. NIKI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of NIKI by reported 13-F value include JANE STREET GROUP, CITADEL ADVISORS, CITIGROUP, based on the most recent SEC filings. NIKI trades on the Nasdaq exchange and files with the SEC under CIK 1734005. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NIKI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Niki BioSolutions, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1734005 →